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A study of lipid profile in non diabetics with stroke. 
 
ABSTRACT 
Aim: The aim is to study the serum lipid profile in non diabetics with 
stroke and to determine significant correlation between them. 
Objective: The objective is to know about the association between 
dyslipidemia and non diabetic stroke patients which can help modify our 
prevention and treatment strategies. 
Type of study: cross  sectional study  
Place of study: Study was conducted on patients of Kilpauk medical 
college hospital  for six months. Patients and controls were tested for 
fasting lipid profile12 hours after overnight fast. 
Participants: Participants were 60 patients of non diabetic stroke and 60 
controls. Among the 60 patients 37 were males and 23 were females. In 
controls there were 37 males and 23 females. Age and sex matched 
controls were selected. Stroke patients with infarct or haemorrage in ct 
brain were included in the study. 
Results: In this study total cholesterol, LDL cholesterol and triglycerides 
were significantly associated with risk of stroke. In this study 56.7% of 
patients had HDL<40 mg/dl, 41.7% had total cholesterol >200 mg/dl, 
65% of them had LDL cholesterol > 100 mg/dl and 43.3 % of patients 
had VLDL >30 mg/dl. 
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INTRODUCTION 
Stroke or a cerebro-vascular accident is an acute neurological 
injury which occurs due to vascular pathology and presents as a brain 
infarction or haemorrhage. Stroke is a medical emergency. The risk 
factors of stroke have been identified. The modification of risk factors in 
stroke has brought down both mortality and morbidity of stroke 
remarkably in the last 30 years. 
Dyslipidemia as a major risk factor for stroke is studied for many 
years. Various studies in different population has shown dyslipidemia is 
associated with stroke. Dyslipidemia is a correctable risk factor. It has 
been shown that reduction of total cholesterol, LDL cholesterol, 
trigycerides, VLDL cholesterol and increasing HDL cholesterol by drugs 
has decreased the incidence of stroke. 
In our study, lipid profile was studied in non-diabetic patients with 
stroke. Diabetes itself is associated with hyperlipidemia and increased 
atherosclerosis which makes it an undisputed risk factor for stroke. The 
atherogenecity of diabetics and non-diabetics are different. So non-
diabetic patients were included in the study. 
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The study is titled as ‘A STUDY OF LIPID PROFILE IN NON-
DIABETICS WITH STROKE’ 
AIM 
 To study serum lipid profile in non-diabetics with stroke and to 
determine significant correlation between them. 
OBJECTIVE 
 Knowledge about the association between dyslipidemia and  stroke 
can help to modify our prevention and treatment strategies towards 
stroke. 
 The study was conducted on 60 non-diabetic stroke patients and 60 
age and sex matched controls who did not have stroke after obtaining 
informed consent.  
 This is a cross-sectional study conducted over a period of 6 months 
in Kilpauk Medical College Hospital. 
 Detailed history, clinical examination, radiological examination, 
serum total cholesterol, LDL, VLDL, HDL, triglycerides were estimated 
by enzymatic method. 
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INCLUSION  CRITERIA 
All patients with stroke with hemorrhage or infarct in CT Brain  
 
EXCLUSION CRITERIA 
 Patients with diabetes mellitus 
 Patients on drugs for dyslipidemia 
 Patients on dietary modification for dyslipidemia 
 Cerebral infarct associated with trauma or tumour 
 
COLLABORATING DEPARTMENTS 
Department of Neurology, KMCH 
Department of Biochemistry, KMCH 
Department of Radiology, KMCH  
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REVIEW OF LITERATURE 
Stroke :- 
 Stroke-1 is defined as abrupt onset of neurological deficit, Which is 
attributable to a focal vascular cause. Stroke is a leading cause of 
mortality and morbidity throughout the world. 
Stroke or Cerebro vascular accident is broadly classified as 
ischemic and hemorrhagic stroke. TIA occurs when all neurological signs 
and symptoms of stroke resolve within 24 hours duration regardless of 
whether imaging evidence of new permanent brain injury is present. If 
ischemia last more 24 hours  but less than 7 days reversible ischemic 
neurological deficit occur. 
Cerebral ischemia is due to reduced blood flow for several second 
,if it persists for minutes infarct or brain tissue death occurs. Intracranial 
hemorrhage due to bleeding into or around the brain may produces stroke. 
Stroke is a  medical emergency. 
Dyslipidemia is a modifiable risk factor for stroke. Aggressive 
management of dyslipidemia decreases the risk of stroke. 
 
5 
 
Epidemiology of Stroke 
 WHO   collaborative study done in 12 countries showed the 
incidence of stroke was about 0.2 to 2.5 per 1000 population per year. In 
India there is not much reliable statistical information. A Random study 
in urban  areas of Vellore showed prevalence rate of hemiplegia in South 
India as 56.9 per 100000. In developed countries like America stroke 
causes 2 lakh death per year. About 7,95,000 people have stroke  
prevalence every year and leading disability and death in America. 
Pathophysiology of Stroke : 
 Stroke is caused by 2 major mechanism ischemia and hemorrhage. 
Ischemic stroke constitutes 80% of total stroke. Ischemic stroke is due to 
diminished or absent blood supply to the neurons resulting in deprivation 
of necessary substrate to neurons. Ischemic damage is rapid because brain 
has no glucose stores. Glucose is the chief source of energy metabolism 
and brain is not able to metabolize glucose anaerobically. Intra cerebral 
hemorrhage constitutes 10 to 15% of all strokes. Bleeding originates from 
deep penetrating vessels leading to pressure effects and disruption of 
connecting pathways. Also certain biochemical substances may cause 
tissue damage by different mechanisms.  
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Cerebral blood flow : 
 Normal cerebral blood flow is 50 to 60 ml / 100g / min. When 
there is ischemia cerebral auto regulatory mechanism compensate the 
reduced blood flow by vasodilatation, opening of collaterals increased 
extraction of oxygen and glucose from blood. Cerebral blood flow less 
than 10ml / 100g/min results in irreversible  neuronal injury. 
Neuronal injury :- 
 Microthrombi formation is triggered by ischemia induced 
activation of destructive vasoactive enzymes which are released by 
endothelium, leucocytes, platelets and other neuronal cells. Following 
release of these enzymes mechanical plugging by leucocytes, 
erythrocytes, platelets and fibrin ensures. 
 Glutamate and aspartate are neuro transmitters, which when 
overacts  leads to development of hypoxic – ischemic neuronal injury. 
This is called excitotoxicity which is triggered due to depletion of energy 
stores. High concentration of glutamate in extra  cellular space in energy 
depleted state results in opening of calcium channels associated with N-
methyl D – aspartate and alpha amino 3 hydroxy 5 methyl 4 isoxanol  
propionate receptors. This persistent membrane depolarisation causes 
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influx of calcium, sodium and chloride along with efflux of Potasium 
ions.  
 The influx of intracellular calcium is responsible for activation of 
destructive enzymes like Lipase, Proteases and Endonucleases which 
allow release of cytokines and other substances leading to destruction of 
cellular integrity Neuronal death occurs by coagulation necrosis and 
apoptosis. Coagulation necrosis process evolves over 6 to 12 hours. In 
apoptosis or programmed cell death mechanism begins within 1 hour 
after ischemic injury. 
 Cerebral injury is greater with elevated temperature, hypoglycemia, 
hyperglycemia, hypercoagulable state, hypotension. Good collateral 
circulation is associated with good outcome. Stroke of short duration and 
slow onset shows better outcome. 
Ischemic Penumbra 
 Penumbra is the ischemic tissue surrounding the infarct whose 
dysfunction can be reversed by treatment within critical period of 2-4 
hours by reperfusion. Rescue of the ischemic Penumbra is the goal of 
revascularization therapies. Ischemic penumbra develops within an hour 
of hypoxia when autoregulatory mechanism fails. 
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Stroke classification : 
Ischemic stroke : 
1) Large vessel disease (eg carotid and vertebral stenosis) 
2) Small vessel stroke (lacunar stroke)  
3) Cardioembolic stroke 
4) Thrombosis 
5) Undetermined 
Primary Hemorrhage: 
1. Intracerebral hemorrhage. 
2. Subarachnoid hemorrhage. 
 
Causes of stroke 
Common causes of stroke 
1. Thrombosis  
- Lacunar stroke 
- Large vessel thrombosis  
- Dehydration 
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2. Embolic occlusion  
Cardio embolic 
- Atrial fibrillation  
- Mural thrombus  
- Dilated cardiomyopathy. 
- Myocardial infarction 
- Valvular lesion  
- Mitralstenosis  
- Bacterial endocarditis  
- Mechanical valve 
Paradoxical embolus  
- Patent foramen ovale  
-  Atrial septal defect 
- Atrial septal aneurysm  
- Echo contrast 
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Artery to Artery 
- Carotid bifurcation  
- Aortic Arch 
- Arterial dissection 
 
UNCOMMON CAUSES OF STROKE 
- Protein c deficiency  
- Protein s deficiency 
- Antithrombin III deficiency 
- Antiphospholipid  syndrome 
- Factor V leiden mutation  
- Malignancy 
- B Thalassemia 
- Sickle cell anemia 
- Polycythemiavera  
- Prothrombin G 20210 Mutation 
- Homocysteinemia  
- Systemic lupus erythematosis 
- Nephrotic syndrome  
- Disseminated intravascular coagulation  
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- Oral contraceptives  
- Venous Sinus thrombosis 
- Vasculitis 
- Fibro muscular dysplasia. 
- Mitral valve calcification 
- Atrial myxoma  
- Libmansachs endocarditis  
- Marantic endocarditis 
- Moya Moya disease  
- Eclampsia 
Risk factors of stroke 
1. Hypertension 
2. Diabetes 
3. Dyslipidemia 
4. Atherosclerosis  
5. Atrial fibrillation 
6. Coronary artery disease  
7. Smoking  
8. Age and sex 
9. Race  
10. Transient Ischemic Attack 
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Hypertension and Stroke :-  
 Risk of stroke rises with systolic and diastolic blood pressure. 
Systolic hypertension is relatively more important than diastolic relative 
risk with hypertension is 2-5. These is about 38% reduction in relative 
risk with treatment. 
Diabetes : 
 In diabetes mellitus the relative risk of stroke is double. But tight 
control of blood sugar has not shown reduction in stroke risk. 
Dyslipidemia is biochemical abnormally in diabetes associated with high 
triglycerides, high LDL, low HDL levels. Diabetes also increases 
atherogenecity. 
Dyslipidemia : 
 Dyslipidemia associated with 1.8 – 2.6 times relative risk of stroke. 
Stroke prevention by aggressive reduction in cholesterol levels 
(SPARCL)-9 trial showed reduction in secondary stroke levels in patients 
with recent stroke on TIA. The multiple risk factor intervention trial 
(MRFIT)-31 with 3,51,000 men with follow up for 6 years showed 
Increased risk of death from ischemic stroke. Increased with very high 
cholesterol. Eastern stroke and coronary heart disease study of 70,000 
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participants showed low cholesterol level associated with low risk of non 
– hemorrhagic stroke.  
Athero sclerosis :- 
 Thrombosis is late state atherosclerosis, atherosclerosis is the 
disease of large and medium sized arteries. The most frequent sites are 
the carotid artery at the carotid sinus, cervical part of the vertebral 
arteries, basilar artery, bifurcation of middle cerebral artery, Posterior 
cerebral artery  and anterior cerebral artery  . The common carotid and 
vertebral artery at the  origin from aorta are frequent sites of 
atheromatous deposits. Atheromatous plaque narrow lumen of an artery 
but complete occlusion is due to Thrombosis. 
Atherosclerosis leads to hardening of arteries. There is thickening 
and loss of elasticity of arterial wall. There is focal intimate thickening 
and lipid accumulation leading to the characteristic plaques and fatty 
streak.  
Atherosclerotic plaques have 3 important components 1. Cells – 
smooth muscle cells, macrophages, leucocyte 2. Intracellular and extra 
cellular lipid deposits 37 connective tissue extra cellular matrix,  
Endothelial damage is a major factor in atherogenesis. Premature 
atherosclerosis is due to hyper lipoproteinemia   and other disorders like 
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nephritic syndrome, alcoholism. Genetic defects in aproproteins may be 
associated with accelerated atherosclerosis according to to Breslow J.C. 
Etal 1992. 
Atrial fibrillation  
 Atrial fibrillation produces emboli which may produce cardio 
embolic stroke. Atrial fibrillation may occur in rheumatic heart disease 
like Mitral stenosis. lone Atrial fibrillation increases risk of stroke. 
Coronary artery disease : 
 In Framingham study-23  it was shown there is a increase in electro 
cardio graphic changes of LVH in ischemic stroke by 10 folds. Non 
specific ST and T wave changes also occur. 
Smoking : 
Framingham study showed increased risk of ischemic stroke in 
smokers. This risk was also associated significantly with the number of 
cigarettes Smoked. In male 40% increased incidence of stroke and in 
female 60% increase in stroke noted. 
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Age and Sex :  
Increasing incidence of stroke with age was shown by Abraham 
and Daniel et al in 1972. Risk is almost double at about 70 years when 
compared to age group of 30 – 39 years. Maximum incidence of stroke 
was shown at 80 years by Agarwal -21 Etal al. Bansal et al showed a male 
to female ratio of 3.2:1 in ischemic stroke. 
Race: 
Stroke is more common in Afro-Caribbean followed by Asians.  
Stroke is less common in Europeans.  
Transient ischemic Attack : 
 Transient ischemic attacks increase the risk of stroke. There is 
remarkable increase of about 5% risk of stroke in each year. 
Clinical features of stroke 
a. Completed stroke 
Completed stroke is rapid onset, and persistence of 
neurological deficit with no progression of neurological 
deficit more than 96 hours. 
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b. Evolving stroke 
Evolving stroke is characterized by gradual 
development of neurological deficit. Evolving stroke 
is due to progression or fluctuation which might be 
because of propagating emboli which migrates,lyses 
and disappears and caused by recurrent artery to artery 
embolization or changes in collateral flow. 
c. Transient ischemic attack 
In transient ishemic attack the neurological deficit has 
occurred focally and recovers completely within 24 
hours. 
d. Reversible ischemic neurological deficit 
In RIND, neurological deficit occurs and completely 
recovers in 1-3 week duration. Signs of ischemia 
longer than 24 hours and within 7 days constitute 
reversible ischemic neurological deficit. 
 
1.Athero-thrombotic stroke 
 Ischemic stroke may be due to thrombosis or embolism. The 
important cause of athero-thrombotic stroke is atherosclerosis and 
hypertension. Different pathogenic mechanisms  development of 
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collateral circulation, auto regulation determine the mode of presentation 
and evolution of stroke. 
Onset of stroke during sleep or immediately getting up from sleep is a 
characteristic feature of thrombotic stroke.  
Clinical features depends upon the type of stroke 
   1. Lacunar infarct 
Lacunar infarct is characterized by tiny infarcts in the deeper portion of 
cerebral hemisphere due to microatheroma or lipohyalinosis of the deep 
penetrating vessels of internal capsule,thalamus,basal ganglia,para 
median region of  brain stem. It constitutes 10-15% of stroke. Mortality is 
rare and recovery is common. 
2. Embolic infarct 
In embolic stroke the source of emboli is mostly cardiac. The emboli 
consists of fragments of mural thrombus and platelet aggregates. The 
most common site of embolic occlusion causing infarction is in the 
middle cerebral artery followed by posterior cerebral artery. Occlusion of 
anterior cerebral artery is rare. Embolic occlusion occurs very rapidly 
during any time of the day or night.  
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The neurological deficit due to emboli may also disappear rapidly due 
to fragmentation of embolus causing evanescent stroke. 
Embolic stroke can become hemorrhagic causing a hemorrhagic 
infarct. Hemorrhagic infarct is an ischemic infarct resulting due to 
bleeding within the necrotized cerebral tissue. Hemorrhagic 
transformation happens when ischemic tissue is reperfused following 
lysis of emboli spontaneously and blood flow to the ischemic area re-
occurs. Hemorrhagic transformation may occur due to persistent 
occlusion of parent artery proximally.  
3.  Hemorrhagic stroke 
 Hemorrhagic stroke may be due to hemorrhage from deep 
penetrating vessels causing injury to brain tissue. It constitutes 10-15% of 
all strokes. It is of two types: 
 sub-arachnoid  
 intra-parenchymal 
Hypertension, coagulation abnormalities are high risk for hemorrhagic 
stroke. 
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Stroke may present in one of the following ways.  
 Stroke in evolution 
 Intermittent progression extending over several hours or days 
 Completed stroke 
 Slow stroke that develops over a period of weeks due to chronic 
hypo-perfusion. 
 
Symptoms of stroke 
 Stroke present as  
 Paralysis 
 Paresis 
 Sensory dysfunction 
 Altered sensorium 
 Language disturbance 
 Higher mental function disturbance 
 Cranial nerve dysfunction 
 Gait dysfunction 
 Headache 
 Cerebellar signs 
 Seizures 
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Differential diagnosis of stroke and TIA: 
 Metastatic cerebral tumours 
 Primary cerebral tumours 
 Cerebral abscess 
 Todd’s paresis 
 Sub-dural hematoma 
 Peripheral nerve lesions (vascular/compressive) 
 Demyelination 
 Hypoglycemia 
 Encephalitis 
 Migrainous aura 
 Meniere’s disease 
 Conversion disorder 
Investigations for stroke patients  
 Basic investigations are done to find out the cause of stroke 
Biochemical test 
1. Fasting blood sugar 
2. Lipid Profile 
3. Blood urea 
4. Creatinine 
5. Electrolytes 
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Hematological Investigations 
1. Complete blood count 
2. Prothrombin time. 
3. Activated Partial Thromboplastin Time. 
4. Peripheral Smear 
5. Hematocrit 
Urine examination for Protein, sugar, deposits 
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Special Investigation : 
Radio graphic imaging studies  
- CT scan (computerized tomography) 
- Magnetic resonance imaging 
- Doppler 
- Ultra sound 
- Digital subtraction angiography. 
 Selected investigations like Hemoglobin electrophoresis, Bone 
marrow, aspiration, ANA, antithrombin III, Lupus anticoagulant, blood 
culture in specific cases.  
Computerized tomography : 
 CT Scan may show hyperacute infarct, subacute infarct and  
chronic infarct. Abnormal perfusion of brain tissue can be made out by 
injection of contrast media and taking CT scan. This perfusion scan is an 
useful guide in the treatment of ischemic stroke. 
Hyperacute infarcts (<12 hours) 
 Signs of early infarct can be identified like hyper attenuating artery 
called as dense MCA sign, insular ribbon sign – gray – white interface 
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loss along with lateral insular effacement of gray white junction along 
cortex and lentiform nucleus obscuration. 
Sub acute infarct : 
After 24 – 48 hours fairly many large vessel infarct are visible on 
CT scan as wedge shaped areas with diminished attenuation. This infarct 
involves gray and white matter with vascular distribution mass effect may 
be present  
Chronic infarct :  
 Well defined focal encephalomalacic areas may be seen on CT 
Scan. The ipsilaterial ventricle enlarges and adjacent sulci is prominent. 
Enhancement may disappear over weeks. Infarct may not be visible on 
CT Scan if it is  lacunar infarcts or brainstem infarctsor if the scan is done 
early. CT Scan done after 2 to 3 weeks may under estimate the size of  
lesion or may not pick up the lesion due to fogging effect.  
MRI Scan :- 
In MRI ischemia becomes visible earlier than CT – scan also 
shows ischemic, necrosis, gliosis. Angiography delineates blood flow and 
vascular lesions. Can show atheromatous plaques in carotid and vertebral 
system.MRI is more sensitive compared to CT in finding stroke afftecting 
brain stem and cerebellum.  
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MRI can distinguish hemorrhagic from ischemic stroke even after 
several weeks. The location of hemorrhagic lesion may indicate vascular 
malformations, saccular aneurysm or myleiod angiopathy. In MRI deep 
and tiny lacunar infract indicate small vessel disease and a peripheral 
infarct may indicate embolic etiology. 
Digital subtraction angiography :  
 Used for visualising cervical and basal intracranial arteries and 
collaterals. Ultrasound and Doppler shows atheromatous plaque and 
stenosis of large vessels especially carotid arteries. 
Duplex ultrasound 
 Extra cranial arterial disease can be detected non-invasively by 
duplex ultrasound. It may show atherosclerotic thromboembolic disease 
in major arteries like carotid. 
Electroencephalography (EEG) 
 Limited value in indicating infarction or differentiation from 
hemorrhage.  
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Complications of acute stroke 
a. Chest infection 
Chest infection can be prevented by nursing the patient in semi-
erect position. Aspiration can be avoided by giving nasogastric feeding 
and avoiding food through mouth. Chest infection can be treated by 
antibiotics and chest physiotherapy. 
b. Epileptic seizures 
Adequate cerebral oxygenation has to be maintained and metabolic 
disturbance has to avoided.  Epileptic seizures are treated with anti-
convulsants. 
c. Deep vein thrombosis/pulmonary embolism 
Deep vein thrombosis is prevented by adequate hydration, anti-
embolism stockings, early mobilization of patients. Heparin can be used 
for high risk patients. Treatment is by using anti-coagulants after 
excluding hemorrhagic stroke. 
d. Pressure sores 
Pressure sores are prevented by frequent turning of patients, 
monitoring pressure areas and by avoiding urinary damage to skin. 
Pressure relieving mattress can be used. 
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e. Urinary infection 
Catherization can be avoided if possible. Urinary tract infection can 
be treated with antibiotics 
f. Constipation 
Constipation is prevented and treated by appropriate aperients 
g. Painful shoulder 
Painful shoulder is avoided by proper shoulder and arm support. 
Physiotherapy helps in relieving the pain. Local steroid injections are also 
used. 
h. Depression and anxiety 
Proper counseling has to be given to the patient to patient regarding 
stroke. Depression is treated with anti-depressants. 
Prognosis of stroke:- 
Prognosis depends on the age of the patient. Abraham & Daniel in 
1972 showed increasing incidence of stroke with age. Male is about 5 
times prone for stroke according to Agarwal-21 et al 1976. Comorbitidities 
like hypertension, diabetes atherosclerosis, hyperlipidemia, increase the 
risk of stroke. 
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Large infarcts with brain swelling, tentorial herniation, 
displacement of central structure have worst prognosis. Coma at onset of 
stroke is poor prognostic  sign. Reoccurrence of stroke influences the 
prognosis. Recovery in embolic stroke is better than thrombotic stroke.  
 
TREATMENT OF STROKE 
Ischemic Stroke :- 
 Cerebral circulation has to maintained by horizontal position of the 
patient, by maintaining systemic circulation and blood pressure. Initially 
cerebral edema both cellular and vasogenic edema  may occur. cerebral 
edema is managed by Dexamethaxone, Mannitol, loop diuretics in low 
doses and oral glycerol. Cerebral vasodilatation is harmful. Intravenous 
thrombolysis can be done within 3 hours of onset of ischemic stroke in 
selected group of patient.  
Indications of thrombolysis in stroke 
1. Clinical diagnosis of stroke 
2. Duration of onset of symptoms to drug administration is less 
than 3 hours. 
3. CT-Scan brain shows no hemorrhage or edema of >1/3 of the 
MCA territory. 
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4. Age more than 18 years. 
5. Consent by the patient or by the surrogate. 
   
Contraindications :- 
- Platelet < 1 lakh, hematocrit <25%  
- Glucose < 50mg/dl  or   > 400 mg/dl 
- Sustained Bp > 185 / 110 despite treatments. 
- Use of heparin within 48 hours and PTT prolongation or INR 
elevated 
- Rapid improvement of symptoms 
- Prior stroke or head injury within 3 month.  
- Any prior intracranial hemorrhage 
- Minor stroke symptoms. 
- Any major surgery in the preceding 14 days  
- Gastrointestinal bleeding in preceding 21 days. 
- Coma or stupor  
- Recent Myocardial infarction : 
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Administration of recombinant tissue Plasminogen :- 
- Recombinant tissue plasminogen is administered at the dose of 0.9 
mg / kg intravenously (maximum 90mg) iv as 10% total dose by 
bolus followed by the remaining dose over 1 hour. 
- Frequent blood pressure monitoring. 
- For 24 hours no other antithrombotic treatment. 
If there is decline in neurological status and  uncontrolled blood 
pressure, stop infusion, give cryoprecipitate and emergency 
reimaging of brain has to be done. 
 Antiplatelet drugs like aspirin are useful in preventing thrombotic  
and embolic strokes. In embolic infarcts prevention of cerebral embolism 
by long term anticoagulant use and treatment of underlying source of 
embolus is needed. 
Rehabilitation of stroke patient :- 
 Rehabilitation of the stroke includes physical, occupational 
and speech therapy. Education of parents and patients regarding 
neurological deficit, preventing complications of immobity and 
encouragement for overcoming the deficit. 
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LIPID METABOLISM 
 Lipids the lipids are heterogeneous group of compounds 
comprising of oils, steroids, fats, waxes and related compounds. They are 
insoluble in water and soluble in non-polar solvents. A Classified as 
simple lipids and complex lipids. 
Simple lipids :  
 Fats  
 Waxes 
Complex lipids 
 Phospholipids 
 Glycospingo  lipids 
 Triglycerides 
 Sulfolipids and aminolipids 
 Precursor and derived lipids 
 Fatty acids 
 Glycerol                      Cholesterol 
 Steroids                           Steroids  hormones 
 Fatty aldehydes  Vitamin D 
 Ketone bodies  
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Uses of lipids 
1) Lipids form structure of cell membrane and is an integral part of 
cell membrane. 
2) Structure of sex hormones. 
3) Good source of energy can be used immediately. Caloric value of 
fat is 9 kilocalories / 1 gm. 
4) Act as electrical insulator allowing rapid propagation of 
depolarization waves in the myelinated  nerves. 
5) Act as thermal blankets because their presence in subcutaneous 
tissue protects the body against heat loss. 
Fatty acids :  
 Derived from glycerol and cholesterol. They have even number of 
carbon atoms and straight chain derivatives. Fatty acids classified as 
saturated  or un saturated fatty acids fatty acids provide for energy 
requirements.   
Unsaturated fatty acids are subdivided as  
 Mono unsaturated fatty acids Example Monoenoic acids,  
 Polyunsaturated fatty acids (eg. Polyenic acids) 
 Eicosinoids (eg. Prostaglandins, thromboxane) 
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Cholesterol  : 
Most important sterol.Cholesterol precursor of bile acids, steroid 
hormones and vitamin D. it is a stable crystalline white substance 
insoluble in water but soluble in chloroform, ether, alcohol. It is found in 
high amounts in nervous tissue, skin, liver, intestine and endocrine 
glands.  
Triglycerides :- 
 Also called as  triacyl glycerols Triglycerides are esters of alcohol 
glycerol and  fatty acids eg.  monoacyl glycerol, diacyl glycerol and 
triacyl glycerol.  
Lipoprotein coats aggregates of triglyceride (80%) phospholipids 
7% and cholesterol (9%) to form chylomicron particles. 
 Phospholipids – complex lipids with phosphate and nitrogenous 
base. Eg. Lecithin and sphingomyelin. 
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Lipoprotein Complex : 
 Lipids in plasma are in the form of lipoprotein complexes. 
Complex of lipid and protein makes it soluble and travel in blood stream 
as lipoprotein complexes.  
Lipoprotein in Plasma 
Lipoprotein Major core Lipids Major Apoproteins 
Chylomicrons Dietary triglyceride B-48, C, E 
HDL Cholesterol A1, A-II 
LDL Cholesterol B-100 
VLDL Endogenous triglyceride B-100, C, E 
Remnants Triglyceride, Cholesterol B-100, E 
 
Tiselius et all showed the existence of two lipoprotein classes alpha 
& Beta lipoprotein electrophoresis. Dangerfield et al identified prebeta 
lipoprotein by zonal electrophoresis 
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Characteristic features and structure of lipoprotein 
 Chylomicr
ons  
LDL HDL VLDL IDL 
Electrophore
sis 
Origin Beta Alpha Pre-beta Broad-beta 
Diameter 90-1000 
nm 
20-25nm 20-25 nm 30-90 nm  
Principal 
core lipid 
 
Exogenous 
triglycerid
e 
 
Cholestero
l 
Triglyceri
de 
Cholesterol 
esters 
Phospholipi
ds 
 
Triglyceri
de 
Cholestero
l esters  
25-35 nm 
Triglyceri
de 
Cholester- 
ol esters  
 
Effect on 
Atheroma 
Nil  3+ Protects 1+ 2+ 
Major 
apoprotein 
AI, AII, B-
48, CII, 
CIII, E 
B-100 
 
A1 and AII 
 
B-100, 
CII, CIII, 
E 
 
B-100, E 
Dietary and 
Drug 
treatment 
Ineffective Resins    
Fibrates, 
nicotonic 
and 
Probucol 
Resins 
Nicotinic 
acid,       
fish oils, 
fibrates 
probucol 
Fibrate 
Nicotinic 
acid,     
fish oils 
Fibrate 
Nicotinic 
acid  
 
Apolipoprotein :  
 Apolipoproteinus are genetically determined components of 
lipoproteins which provide structural stability to lipoproteins like 
solubilising lipids, activating enzymes and initiating receptor rmediated 
clearance of the lipoproteins. 
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Classification of Apolipoprotein . 
Apoprotein A – AI, AII 
Apoprotein B – B48, B100 
Apolipoprotein C – CII, CIII, CIV 
Apolipoprotein E – E2, E3, E4 
Apoprotein A : 
 Apoprotein AI - AII are major apoprotein of HDL and removes 
excess cholesterol form surface of cells. Apolipoprotein A is 
demonstrated as independent risk factor for cardiovascular disease 
development and better predictor  of coronary artery disease than HDL.  
Apoprotein B : 
 Apoprotein B48 is major structural protein of chylomicrons. 
Apoprotein B-100 is major structural protein of VLDL and LDL essential 
for secretion of VLDL from liver and ligand removal of LDL from 
receptor of LDL. It may be elevated in patients with coronary artery 
disease. 
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Apoprotein C :  
 Found in all lipoproteins. Apoprotein C regulate the active 
lipoprotein lipase. ApoC Removes chylomicrons and VLDL by liver 
.Apoprotein C2 absence causes hypertriglyceridemia. Apoprotein C3 
prevents the catabolism of VLDL and Chylomicrons. 
Apoprotein E :- 
 Apoprotein E is present in VLDL and Chylomicrons. It is required 
for catabolism of remnants by specific receptors on liver  
Lipoprotein Metabolism :- 
 Lipoprotein system is used to transport lipids in exogenous system 
triglycerides are converted to chylomicrons rich in cholesterol by 
Lipoprotein lipase. In the  endogenous system VLDL is secreted by the 
liver and converted to IDL. IDL is converted to LDL which is rich in 
cholesterol. 
Chylomicrons : 
Chylomicrons are derived from dietary fats and cholesterol which 
is absorbed from the intestine. Chylomicrons are secreted in to the lymph 
travel through thoracic duct then enter the systemic circulation. 
37 
 
Chylomicrons interact with lipoprotein lipase leading to  hydrolysis of 
triglyceride to fatty acid and glycerol. After  lipolysis chylomicrons 
remnant is released back into circulation which is cleared rapidly by liver 
by recognition of apoprotein E. Newly secreted chylomicrons are rich in 
apoproteins B48  and A1. Newly secreted chylomicrons acquired 
apoproteins C & E from HDL Particles.  
VLDL Metabolism 
 VLDL is synthesized by the liver endogenously the main code lipid 
is triglyceride, apoprotein B100, C , E are present.  Metabolism of VLDL 
and chylomicrons are similar VLDL transports triglyceride to the tissues 
which is used as fuel in adipose tissues the transported triglyceride may 
be used for storage. VLDL interacts with lipoprotein lipase, VLDL 
remnant. This remnant produced is converted to LDL or cleared by liver 
by identifying apoprotein E. 
LDL Metabolism :  
 Major component of LDL is cholesterol LDL delivers cholesterol 
to tissue through as specific high affinity LDL receptor which controls 
uptake of cholesterol by the cells. LDL receptor controls intra cellular 
synthesis of cholesterol. Through LDL receptor a portion of the LDL 
particles catabolised by the liver and the remaining LDL remnant is 
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plasma. Function of LDL is to supply cholesterol to extra hepatic cells 
like adrenal cortical cells. Lymphocytes muscles cells and renal cells. 
They have LDL receptor on the surface. So cholesterol is used and is 
available to the cell for membranes synthesis. Most cholesterol released 
from extra hepatic tissue is then transported to the liver for excretion. 
HDL Metabolism :  
 HDL is needed for removing cholesterol from Peripheral tissue to 
the liver and for metabolising  VLDL chylomicrons. Liver and intestine 
secrete nascent HDL it takes of Cholesterol from VLDL and 
chylomicrons to become HDL3. Enzyme LCAT -Lecithin cholesterol acyl 
transferase transforms HDL3 to HDL2 . HDL2  transfers cholesterol to 
VLDL or cholesterol directly to liver after conversion to HDL3 by hepatic 
triglyceride lipase enzyme.  
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Fredrickson Classification of hyperlipoproteniemia  
Phenotype Lipo 
Protein 
Elevated 
Chylomicron  IIa 
LDL 
II B LDL and 
VLDL 
III 
Chylomicron 
and VLDL 
IV  
VLDL 
V 
Chylomicron 
and VLDL 
Triglyceride ↑↑↑ N ↑ ↑↑ ↑↑ ↑↑↑ 
Cholesterol ↑ ↑↑↑ ↑↑ ↑↑ N/↑ ↑↑ 
LDL – 
Cholesterol 
↓ ↑↑↑ ↑↑ ↓ ↓ ↓ 
HDL – 
Cholesterol  
↓↓↓ N / ↓ ↓ N ↓↓ ↓↓↓ 
Plasma 
Appearance  
Opalescent Clear Clear Turbid Turbid Opalescent 
Pancreatitis +++ 0 0 0 0 +++ 
Xanthoma Eruptive  Tendon, 
tuberous 
None palmar Tubero 
eruptive  
None Eruptive 
Peripheral 
atherosclerosis  
0 + + ++ +/- +/- 
Coronary 
atherosclerosis 
0 +++ +++ +++ +/- +/- 
Genetic  
Nomenclature 
FCS FH, FDB, 
ADH, ARH,  
FCHL FDBL FHTG FHTG 
Molecular 
defects 
LPL and 
APOCII 
LDL receptor 
APO-B-100, 
PCSka, 
LDLRAP, ABC 
G5, ABC G8 
 APOE APOA-V APO AV and 
GPIHBPI 
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ABBREVIATIONS: 
ADH – Autosomal dominant Hypercholesterolemia  
APO – Apolipoprotein 
ARH – Autosomal  recessive hypercholesterolemia. 
FCHL – Familal Combined hyperlipidemia  
FCS – Familial chylomicronemia   syndrome 
FDB – Familial defective APO B 
FDBL – Familial dysbetalipoproteinemia 
FH – Familial hyper cholesterolemia. 
FGTG – Familial hyper triglyceridemia  
LPL – Lipo Protein Lipase 
GPL, HBP – Glycosyl Phosphatidylinositol – anchored high density 
Lipo protein binding protein. 
LDL RAP – LDL receptor associated  protein  
N – Normal  
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Primary disorders of Plasma lipoprotein 
Familial lipoprotein lipase deficiency type 1 
b. Deficiency of lipoprotein lipase or abnormal lipoprotein 
lipase or apoprotein CII deficiency causing inactive LPL 
c. Autosomal recessive, 1/1000000 incidence. 
d. Hypertriglyceridemia 
e. Chylomicrons elevated 
f. VLDL elevated 
g. Cholesterol levels also elevated but lesser degree 
h. Clinical finding 
i. Eruptive Xanthomas 
ii. Hepato Splenomeghaly 
iii. Pancreatitis. 
Familial hypercholesterolemia – Type II A 
- Defect in LDL receptor or mutation in ligand of apo – B – 100 
- Autosomal dominant , 1/500 incidence 
- Elevated LDL and hypercholesterolemia 
- Normal triglyceride  
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- Elevated LDL is due to increased production of LDL from IDL 
since there is delayed removal of IDL by LDL receptor mediated 
endocytosis.   
Clinical feature 
- Coronary artery disease 
- Tendon xanthomas 
Familial type II hyperlipoproteinemia  
- Deficiency in remant clearance due to abnormality in apo E. 
- Isoforms E3 and E4 which react with E receptor are deficient. 
- Autosomal recessive 1/10000 incidence 
- Increased chylomicrons 
- Increased VLDL remnants. 
Clinical feature 
- Palmar and tubereruptive xanthomas  
- Coronary artery disease 
- Peripheral vascular disease 
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Familial hypertricylglycerolemia type IV 
- Over production of VLDL 
- Impaired catabolism of VLDL 
- Increase intake of carbohydrates, obesity, insulin resistance, 
alcohol use, estrogen, treatment increase VLDL synthesis, 
exacerbate the syndrome.  
- Plasma triglycerides increases. 
- Increased VLDL 
- Reduced plasma HDL 
Familial hyperalphalipoprotenimia  
- Increased concentration of HDL 
- Beneficial to health 
Hepatic lipase deficiency 
- Deficiency of hepatic lipase  
- Autosomal recessive < 1/1000000 
- VLDL remnants increased 
- HDL increased 
- Tendon xanthomas and coronary heart disease present. 
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Familial lecithin cholesterol acyltranferase (LCAT) deficiency 
- Absence of LCAT 
- Mutation in LCAT gene. 
- Low Plasma HDL 
- Hypertriglyceridemia 
- VLDL abnormal 
- Associated with anemia, progressive corneal opacification, 
progressive renal insufficiency.  
Familial lipoproteinen excess  
- Lipoprotein is  
- Premature coronary artery disease 
- Thrombolysis due to fibrinolysis inhibition. 
Hypolipoproteinemias  
- Defect in loading of lipid in apo B. 
- No chylomicrons 
- No VLDL 
- No LDL  
- Triacylglycerols low. 
- Intestinal Malabsorption 
- Accumulationof tricicylglycerols in intestine and liver.  
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Familial alpha lipoprotein deficiency 
- Tangier disease 
- Fish-eye disease 
Apo-A-1 deficiency 
- Near absence of HDL 
- Low LDL level 
- Atherosclerosisoccurs. 
Hyperlipoprotenemia secondary to other diseases 
a) Diabetes 
b) Nephrotic syndrome 
c) Hypothyroidism. 
d) Pancreatitis 
e) Biliary obstruction 
Management of hyperlipidemia :  
 The national cholesterol education program was started in 1985 do 
decrease the prevalence of elevated blood cholesterol levels. In 1987 
adult treatment panel guidelines were released for treating the high 
cholesterol levels.  
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 This programme recommends all individuals over the age of 20 
years and children who are at risk due to atherosclerosis in family must 
be screened for serum cholesterol which can be collected any time. If S. 
Cholesterol is less than 200 mg/dl then the person has to repeat the test 
after 5 years and no further evaluation is needed. Patients with S. 
Cholesterol > 200mg/dl and other risk factors or with S.cholesterol more 
than 240mg/dl should undergo complete lipid profile on fasting sample.  
Desirable. S. Cholesterol <200mg/dl.  
Borderline high 200 – 239 mg/dl  
High > 240mg/dl 
NCEP recommends the following guidelines for LDL levels 
Desirable <100 mg/dl 
Borderline 100 – 129 mg/dl 
High risk >130 mg/dl 
High risk patients should be started with dietary therapy. High risk 
patients as described by NCEP are patients with definite coronary heart 
disease or two or more cardio vascular risk factors like male, family 
history of CHD, smoking, hypertension, diabetes, obesity and low HDL 
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levels. Drug therapy is started for patients who after dietary therapy have 
LDL > 129mg/dl and high risk status with HDL<40mg/dl. 
The aim of therapy is to reduce LDL to less than 100 mg/dl and in 
high risk patients to less than 70mg/dl. 
Dietary therapy  
 Dietary therapy is the primary step in the management of patients 
with hyperlipidemia. In some patients dietary management alone can 
control hyperlipidemia. The diet advised consists of saturated fat <7% of 
total calories. Monounsaturated fat upto 20% of total calories 
polyunsaturated fat 10% of total calories carbohydrate content should be 
50 – 60% of total calories, protein, content 15% of total calories, 
cholesterol content must be less than 200mg/dl. Moderate physical 
activity leading to expenditure of 200 kcal/day is needed. 
Drug therapy : 
 If dietary therapy fails drug therapy has to be started. Different 
drugs are available for drug therapy. 
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ATP III LDL Cholesterol goals and threshold for drug therapy and 
therapeutic lifestyle changes (TLC) 
Category Start TLC 
Start drug 
therapy LDL – C Goal 
Very high risk Any LDL – C 
LDL C > 70 
mg/dl 
<70 mg/dl 
High Risk >100 mg/dl LDL – C >, 100 
mg/dl 
< 100 mg/dl 
Moderately high 
risk > 130 mg / dl 
LDL –C > 130 
mg/dl < 130mg/dl 
Moderate risk >130 mg/ dl LDL-C > 160 
mg/dl 
< 130 mg/dl 
Lower risk > 160 mg/dl LDL –C > 
190mg/dl 
< 160 mg/dl 
 
The drug used in dyslipidemia  are 
1. Cholesterol resins – Cholesterol resins used are colestyramine, 
colestipol, colesevelam. 
 Lower LDL level 15 to 30% 
 Reduce risk or coronary artery disease (new England Journal of 
Medicine, 1999) 
 May cause hyper triglyceridemia and should not be used alone. 
 Acts by absorption  of  bile acids in the intestine so there is no  
reasorption of bile acids in terminal ileum and normal  
enterohepatic circulation of bile acids is prevented. Then  
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cholesterol is converted to bite acids leading to decreased 
cholesterol. This cholesterol stimulates LDL receptor activity 
leading to decreased levels of LDL in plasma. 
 Dose, cholestyramine 4 to 24 gm po in divided doses.  
Colestipol 2 to 16 gm PO in divided doses.  
Drug interaction:  
Decrease oral reabsorption  of  Amiadarone, Statins, Warfarin, 
digoxin. 
Side effects: 
Bloating, Nausea, abdominal pain, constipation, flatulence. 
Nicotinic acid :- 
 Lowers LDL cholesterol by 15%  
 Lowers triglyceride levels 20 to 50% .  
 HDL cholesterol increased by 35% (Arch internal medicine 
1994) 
 Acts by inhibiting secretion of LDL in the liver thereby 
decreasing LDL levels. Also diminishes mobilisation of free 
fatty acid from the adipose tissue.  
 Dose : 1 to 3 gm orally in 2 or 3 divided does with meals. 
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Side effects : 
Headache, nausea, pruritus, bloating, hyperuricemia, 
hyperglycemia and elevated liver enzymes. Avoided in Gout, Liver 
disease, uncontrolled diabetes mellitus.  
STATINS :  
 HMG coAreductase inhibitors 
 Lowers LDL cholesterol 30 – 50% 
 Act by inhibiting HMG coA reductase  the rate limiting step of 
cholesterol synthesis. 
 Statins increase LDL receptor activity in the liver, removes 
LDL and VLDL remnants from plasma. 
 Statins other important pleiotropic actions like improvement of 
endothelial function, antioxidant properties, immune 
modulatory action, inhibition of inflammatory responses, 
increased bioavailability of nitric oxide, and atherosclerotic 
plaque stabilization.  
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Dose : 
 Atorvostation 10 – 80 mg, orally /day 
 Fluvastatin 20 – 80 mg orally / day 
 Lovastatin 10-80 mg orally / day 
 Rosuvastatin 5- 40 mg orally/ day 
 Pravastatin 10-80 mg orally/ day 
Side Effects : 
 Gastrointestinal upsets abdominal pain, diarrhea, bloating, 
headache, fatigue, rash. Elevation of liver transaminases  2 or 3 times 
may occur with statin this is dose dependant and is reversible on drug 
withdrawal. Liver function test to be performed before starting 
statins.Muscle pain and muscle weakness can occur without creatinine 
kinase elevation. Muscle pain and weakness is dependant on the dose of 
the drug, age, body size, renal parameters and use of other medications. 
Statins have increased risk of rhabdomyolysis (new England 
journal of Medicine 1999) when taken with drugs which undergo 
metabolism by cytochrome P450 like gemfibrozil, erythromycin, 
clarithromycin, Ketoconazole, cyclosporin. 
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Ezetimibe : 
 Cholesterol absorption inhibitior acts on the brush border of 
small intensine. 
 Decrease LDL by 18% when used as monotherapy (American 
journal of cardiology 2002) 
 Dose 10 mg orally once a day. 
 
Side effects :- 
GI symptoms like nausea, vomiting, diarrhea and myalgias. 
Fibric acid derivatives 
 Lower triglyceride levels 30 to 50% 
 Increase HDL levels10 to 35% 
 Lower LDL cholesterol level by 5% to 25% 
 Acts by increasing lipoprotein lipase activity and increase 
VLDL clearance 
Dose :  
 Gemfibrozil 600 mg orally twice before meals 
 Fenofibrate 48 to 145 mg orally per day. 
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Side effects :  
Abdominal discomfort, Myalgia, increased incidence of gall stones, 
pruritus and rash. 
Omega 3 Fatty acids :- 
 Lowers triglyceride 
 Ingredients are Eicosapetaenoic acid and docosahexaenoic acid. 
Dose 1 to 6 gm of Eicosa pentaenoic acid and 
docosahexaenoic acid. 
  
54 
 
METHODOLOGY 
COLLECTION OF BLOOD SAMPLE 
Blood samples were collected from all patients after an overnight 
fast of minimum 12 hours. Previous day patient was advised to have light 
fat free diet. Sample collected from cubital fossa. Tourniquet was 
released just before sample collection to avoid increased serum lipids 
artefactually. 10ml of blood was drawn in sterile syringes and blood was 
transferred to dry glass tubes.  
 
PREPARATION OF SERUM 
 Serum for HDL was separated within two hours of collection. The 
sample was centrifuged at 5000 rpm for 10 minutes in a centrifuge tube. 
The clear serum was pipetted out and stored at 4 degree centigrade. 
Samples were analysed within 24 hours. 
 
SERUM TOTAL CHOLESTEROL ESTIMATION. 
 Serum total cholesterol is measured by cholesterol peroxidase 
method. This method has extended stability. Reconstituted reagent is 
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stored at 2-8 degree centigrade and is stable for 90 days. This method is 
linear up to 500 mg/dl.  
 
PRINCIPLE 
Enzymatic calorimetric method of determination of total 
cholesterol.  
The following reactions  
                                  Cholesterol esterase 
Cholesterol + water --------------------------> fatty acid+ cholesterol 
   Cholesterol esterase 
Cholesterol + oxygen ---------------------------> 4-cholesten-3-one+H2O2 
                                             Peroxidase 
2H2O2+ phenol+4-aminoantipyrine------> red quninone+4H20 
The reagent is stable when stored at 2-8 degree centigrade upto 
expiry date. 
The reagent is linear upto the value of 500 mg/dl, if the 
concentration is greater than 500 mg/dl, the sample has to be diluted with 
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normal saline and the assay has to be repeated and the result has to be 
repeated with dilution fraction. 
 
REAGENTS 
CHOLESTEROL R1:2x50 ml/4x50ml/4x100ml/2x405ml 
Phenol-24mmol/L 
Sodium cholate- 0.2mmol/L 
Pipes buffer(pH-6.9)-50mmol/L 
 
CHOLESTEROL R2:2x50ml/4x50ml/4x100ml/8x100ml 
Cholesterol esterase >200U/L 
Peroxidase >1000U/L 
Cholesterol oxidase<250U/L 
4-aminoantipirine – 0.5mmol/L 
 
CHOLESTEROL STANDARD:1x5ml/1x5ml/1x5ml/2x5ml 
Cholesterol standard concentration 200mg/dl 
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PREPARATION OF WORKING REAGENT 
Dissolve reagent R1 and R2 of cholesterol as shown on the label 
SAMPLE- Serum 
 BLANK STANDARD SAMPLE 
Working reagent 1000µL 1000µL 1000µL 
Standard - 10µL - 
Sample 
 - - 10µL 
 
Mix the contents and incubate at 37 degree centigrade for 5 
minutes. Absorbance of the standard and sample to be measured against 
reagent blank. 
 
CALCULATION 
Cholesterol conc(mg/dl)= absorbance of sample/ absorbance of 
standard x 200 
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ESTIMATION OF SERUM HDL CHOLESTEROL: 
The reagent measures HDL cholesterol in serum/plasma by 
precipitation method, linear up to 125 mg/dl. 
 
REAGENT COMPOSITION 
HDL CHOLESTEROL REAGENT : 4x25ml 
Magenesium chloride-1mmol/L 
Phosphotungstate-14mmol/L 
 
HDL CHOLESTEROL CONCENTRATION STANDARD-1x5ML 
HDL CHOLESTEROL CONCENTRATION :50mg/L 
 
PRINCIPLE 
 VLDL,LDL,Chylomicrons are precipitated by magnesium and 
phosphotungstate. High density lipoproteins are concentrated in the 
supernatant following centrifugation is measured by enzymatic methods. 
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REAGENT 
Reagent is stored at 2-8 degree centigrade and is stable upto expiry 
date. The reagent is linear upto the value of 125 mg/dl, if the 
concentration is greater than 125 mg/dl, the sample has to be diluted with 
normal saline and the assay has to be repeated and the result has to be 
repeated with dilution fraction. 
The reagent can be used readily. 
SAMPLE: serum/plasma 
PROCEDURE 
SAMPLE 300µL 
HDL reagent 300µL 
 
Mix both reagent and sample allow it to stand for 10 minutes at 
room temperature. Remix and centrifuge for 10 minutes at 4000rpm. 
Separate the clear precipitant within one hour and HDL cholesterol 
concentration has to be determined. 
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 BLANK STANDARD SAMPLE 
Working reagent 1000µL 1000µL 1000µL 
Standard    (HDL) - 50µL - 
Sample 
(HDL Supernatant) - - 50µL 
 
Mix the contents and incubate at 37 degree centigrade for 5 
minutes. Absorbance of the standard and sample to be measured against 
reagent blank. 
 
CALCULATION 
HDL Cholesterol conc. (mg/dl)= absorbance of sample/ absorbance 
of standard X NX2 
Where 2 is dilution factor of sample 
N is the standard concentration 
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SERUM LDL 
The immunological principle together with enzymatic assay of 
cholesterol is used for estimation of LDL directly. 
LDL=Total cholesterol – (HDL Cholesterol + triglyceride/5) 
SERUM TRIGLYCERIDE 
GPO-PAP methodology is used for measuring triglycerides in 
serum or plasma. 
Reagent is stored at 2-8 degree centigrade and is stable up to expiry 
date. The reagent is linear up to the value of 1000 mg/dl, if the 
concentration is greater than 1000 mg/dl, the sample has to be diluted 
with normal saline and the assay has to be repeated and the result has to 
be repeated with dilution fraction. 
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PRINCIPLES 
Enzymatic determination of triglycerides is by following reaction 
 
        Lipoprotein lipase 
Triglyceride + water  ------------------------>   glycerol+fatty acid 
 
      Glycerol kinase 
Glycerol+ATP----------------------------------->glycerol-3- phosphate+ADP 
 
               Glycerol 3 phosphate oxidase 
Glycerol 3 phosphate+ oxygen -------------> dihydroxyl acetone  
       phosphate+H202 
 
       POD 
H202+4-aminoantipirine+P-chloro phenol -------->red quinoneimine 
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REAGENT COMPOSITION 
TRIGLYCERIDE RI: 3X10ml/5X25ml/5X50ml 
Potassium ferrocynate- 10mmol/L 
Magnesium salt-17mmol/L 
4-aminoantipyrine-0.9mmol/L 
P-chlorophenol-5.3mmol/L 
Pipes buffer(pH 7)-50mmol/L 
Lipoprotein lipase ≥1800 U/L 
Glycerol kinase ≥ 450 U/L 
Peroxidase ≥ 450 U/L 
Glycerol 3 phosphate oxidase ≥ 3500 U/L 
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TRIGLYCERIDE STANDARD CONCENTRATION – 200mg/dl 
SAMPLE- serum/plasma 
 BLANK STANDARD SAMPLE 
Working 
reagent 1000µL 1000µL 1000µL 
Standard - 10µL - 
Sample 
 - - 10µL 
 
Mix the contents and incubate at 37 degree centigrade for 5 
minutes. Absorbance of the standard and sample to be measured against 
reagent blank. 
Triglyceride concentration (mg/dl)= absorbance of sample/ 
absorbance of standard X 200 
 VLDL concentration(mg/dl)= triglyceride/5 
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Group Statistics
60 58.62 12.209 1.576
60 58.20 11.725 1.514
6024.9113 2.92865 .37809
6024.2908 1.83463 .23685
Diagnosis
Non Diabetics with stroke
Control
Non Diabetics with stroke
Control
Age
BMI
N MeanStd. Deviation
Std. Error
Mean
Independent Samples Test
.002 .964 .191 118 .849 .417 2.185 -3.911 4.744
.19117.808 .849 .417 2.185 -3.911 4.744
9.364 .003 1.391 118 .167 .62050 .44615-.262991.50399
1.39199.127 .167 .62050 .44615-.264741.50574
Equal variances
assumed
Equal variances
not assumed
Equal variances
assumed
Equal variances
not assumed
Age
BMI
F Sig.
Levene's Test for
Equality of Variances
t df Sig. (2-tailed)
Mean
Difference
Std. Error
DifferenceLower Upper
95% Confidence
Interval of the
Difference
t-test for Equality of Means
STATISTICAL ANALYSIS 
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Age Group * Diagnosis Crosstabulation
5 5 10
8.3% 8.3% 8.3%
29 29 58
48.3% 48.3% 48.3%
26 26 52
43.3% 43.3% 43.3%
60 60 120
100.0% 100.0% 100.0%
Count
% within Diagnosis
Count
% within Diagnosis
Count
% within Diagnosis
Count
% within Diagnosis
< 40 Years
41 - 60 Years
> 60 Years
Age
Group
Total
Non Diabetics
with stroke Control
Diagnosis
Total
Chi-Square Tests
.000a 2 1.000
.000 2 1.000
.000 1 1.000
120
Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
0 cells (.0%) have expected count less than 5. The
minimum expected count is 5.00.
a. 
AGE GROUP X DIAGNOSIS 
TABLE 1 
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BMI * Diagnosis Crosstabulation
1 0 1
1.7% .0% .8%
28 40 68
46.7% 66.7% 56.7%
30 20 50
50.0% 33.3% 41.7%
1 0 1
1.7% .0% .8%
60 60 120
100.0% 100.0% 100.0%
Count
% within Diagnosis
Count
% within Diagnosis
Count
% within Diagnosis
Count
% within Diagnosis
Count
% within Diagnosis
UNDER WEIGHT
NORMAL
OVER WEIGHT
OBESE
BMI
Total
Non Diabetics
with stroke Control
Diagnosis
Total
Chi-Square Tests
6.118a 3 .106
6.915 3 .075
3.601 1 .058
120
Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
4 cells (50.0%) have expected count less than 5. The
minimum expected count is .50.
a. 
BMI X DIAGNOSIS 
TABLE 2 
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Crosstab
37 37 74
61.7% 61.7% 61.7%
23 23 46
38.3% 38.3% 38.3%
60 60 120
100.0% 100.0% 100.0%
Count
% within Diagnosis
Count
% within Diagnosis
Count
% within Diagnosis
Male
Female
Sex
Total
Non Diabetics
with stroke Control
Diagnosis
Total
Chi-Square Tests
.000b 1 1.000
.000 1 1.000
.000 1 1.000
1.000 .574
.000 1 1.000
120
Pearson Chi-Square
Continuity Correctiona
Likelihood Ratio
Fisher's Exact Test
Linear-by-Linear
Association
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
Exact Sig.
(2-sided)
Exact Sig.
(1-sided)
Computed only for a 2x2 tablea. 
0 cells (.0%) have expected count less than 5. The minimum expected count is 23.
00.
b. 
Sex X Diagnosis 
TABLE 3 
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Crosstab
14 0 14
23.3% .0% 11.7%
46 60 106
76.7% 100.0% 88.3%
60 60 120
100.0% 100.0% 100.0%
Count
% within Diagnosis
Count
% within Diagnosis
Count
% within Diagnosis
Yes
No
Smoking
Total
Non Diabetics
with stroke Control
Diagnosis
Total
Chi-Square Tests
15.849b 1 .000
13.666 1 .000
21.263 1 .000
.000 .000
15.717 1 .000
120
Pearson Chi-Square
Continuity Correctiona
Likelihood Ratio
Fisher's Exact Test
Linear-by-Linear
Association
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
Exact Sig.
(2-sided)
Exact Sig.
(1-sided)
Computed only for a 2x2 tablea. 
0 cells (.0%) have expected count less than 5. The minimum expected count is 7.
00.
b. 
Smoking X Diagnosis 
TABLE 4 
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Crosstab
14 0 14
23.3% .0% 11.7%
46 60 106
76.7% 100.0% 88.3%
60 60 120
100.0% 100.0% 100.0%
Count
% within Diagnosis
Count
% within Diagnosis
Count
% within Diagnosis
Yes
No
Hypertension
Total
Non Diabetics
with stroke Control
Diagnosis
Total
Chi-Square Tests
15.849b 1 .000
13.666 1 .000
21.263 1 .000
.000 .000
15.717 1 .000
120
Pearson Chi-Square
Continuity Correctiona
Likelihood Ratio
Fisher's Exact Test
Linear-by-Linear
Association
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
Exact Sig.
(2-sided)
Exact Sig.
(1-sided)
Computed only for a 2x2 tablea. 
0 cells (.0%) have expected count less than 5. The minimum expected count is 7.
00.
b. 
Hypertension X  Diagnosis 
TABLE 5 
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Independent Samples Test
77.662 .000 5.463 118 .000 47.567 8.707 30.325 64.809
5.463 84.419 .000 47.567 8.707 30.253 64.880
24.745 .000 2.230 118 .028 13.350 5.985 1.497 25.203
2.230 87.069 .028 13.350 5.985 1.454 25.246
13.005 .000 -1.332 118 .186 -2.117 1.590 -5.264 1.031
-1.332 104.021 .186 -2.117 1.590 -5.269 1.035
57.909 .000 6.209 118 .000 48.9567 7.8852 33.3418 64.5715
6.209 85.422 .000 48.9567 7.8852 33.2799 64.6334
5.372 .022 1.624 118 .107 6.6383 4.0864 -1.4539 14.7305
1.624 61.081 .109 6.6383 4.0864 -1.5327 14.8094
3.274 .073 -2.844 118 .005 -.15148 .05326 -.25695 -.04602
-2.844 97.487 .005 -.15148 .05326 -.25718 -.04579
36.058 .000 5.674 118 .000 1.55168 .27346 1.01015 2.09322
5.674 77.853 .000 1.55168 .27346 1.00724 2.09613
Equal variances
assumed
Equal variances
not assumed
Equal variances
assumed
Equal variances
not assumed
Equal variances
assumed
Equal variances
not assumed
Equal variances
assumed
Equal variances
not assumed
Equal variances
assumed
Equal variances
not assumed
Equal variances
assumed
Equal variances
not assumed
Equal variances
assumed
Equal variances
not assumed
T.CHOLESTEROL
TGL
HDL
LDL
VLDL
HDL | LDL
TC | HDL
F Sig.
Levene's Test for
Equality of Variances
t df Sig. (2-tailed)
Mean
Difference
Std. Error
Difference Lower Upper
95% Confidence
Interval of the
Difference
t-test for Equality of Means
T-TEST 
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Ranks
60 66.28 3976.50
60 54.73 3283.50
120
60 45.01 2700.50
60 75.99 4559.50
120
Diagnosis
Non Diabetics with stroke
Control
Total
Non Diabetics with stroke
Control
Total
VLDL
HDL | LDL
N Mean RankSum of Ranks
Test Statisticsa
1453.500 870.500
3283.500 2700.500
-1.820 -4.880
.069 .000
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
VLDL HDL | LDL
Grouping Variable: Diagnosisa. 
Mann-Whitney Test 
 
 
 
 
 
 
 
 
 
 
  
73 
 
Crosstab
26 54 80
43.3% 90.0% 66.7%
10 3 13
16.7% 5.0% 10.8%
24 3 27
40.0% 5.0% 22.5%
60 60 120
100.0% 100.0% 100.0%
Count
% within Diagnosis
Count
% within Diagnosis
Count
% within Diagnosis
Count
% within Diagnosis
< 200
200 - 240
> 240
T.CHOLESTEROL
Total
Non Diabetics
with stroke Control
Diagnosis
Total
Chi-Square Tests
29.903a 2 .000
32.580 2 .000
28.484 1 .000
120
Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
0 cells (.0%) have expected count less than 5. The
minimum expected count is 6.50.
a. 
T.Cholesterol X  Diagnosis 
TABLE 6 
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Crosstab
35 52 87
58.3% 86.7% 72.5%
16 4 20
26.7% 6.7% 16.7%
9 4 13
15.0% 6.7% 10.8%
60 60 120
100.0% 100.0% 100.0%
Count
% within Diagnosis
Count
% within Diagnosis
Count
% within Diagnosis
Count
% within Diagnosis
< 150
150 - 199
>_ 200
TGL
Total
Non Diabetics
with stroke Control
Diagnosis
Total
Chi-Square Tests
12.445a 2 .002
13.027 2 .001
8.828 1 .003
120
Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
0 cells (.0%) have expected count less than 5. The
minimum expected count is 6.50.
a. 
TGL X Diagnosis 
TABLE 7 
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Crosstab
32 22 54
53.3% 36.7% 45.0%
28 38 66
46.7% 63.3% 55.0%
60 60 120
100.0% 100.0% 100.0%
Count
% within Diagnosis
Count
% within Diagnosis
Count
% within Diagnosis
< 40
>_ 40
HDL
Total
Non Diabetics
with stroke Control
Diagnosis
Total
Chi-Square Tests
3.367b 1 .067
2.727 1 .099
3.384 1 .066
.098 .049
3.339 1 .068
120
Pearson Chi-Square
Continuity Correctiona
Likelihood Ratio
Fisher's Exact Test
Linear-by-Linear
Association
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
Exact Sig.
(2-sided)
Exact Sig.
(1-sided)
Computed only for a 2x2 tablea. 
0 cells (.0%) have expected count less than 5. The minimum expected count is 27.
00.
b. 
HDL X  Diagnosis 
TABLE 8 
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Crosstab
21 55 76
35.0% 91.7% 63.3%
5 0 5
8.3% .0% 4.2%
10 3 13
16.7% 5.0% 10.8%
24 2 26
40.0% 3.3% 21.7%
60 60 120
100.0% 100.0% 100.0%
Count
% within Diagnosis
Count
% within Diagnosis
Count
% within Diagnosis
Count
% within Diagnosis
Count
% within Diagnosis
< 100
100 - 130
131 - 160
>160
LDL
Total
Non Diabetics
with stroke Control
Diagnosis
Total
Chi-Square Tests
42.595a 3 .000
48.613 3 .000
37.318 1 .000
120
Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
2 cells (25.0%) have expected count less than 5. The
minimum expected count is 2.50.
a. 
LDL X  Diagnosis 
TABLE 9 
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Crosstab
43 10 53
71.7% 16.7% 44.2%
17 50 67
28.3% 83.3% 55.8%
60 60 120
100.0% 100.0% 100.0%
Count
% within Diagnosis
Count
% within Diagnosis
Count
% within Diagnosis
< 0.39
>_ 0.4
HDL |
LDL
Total
Non Diabetics
with stroke Control
Diagnosis
Total
Chi-Square Tests
36.801b 1 .000
34.604 1 .000
39.122 1 .000
.000 .000
36.494 1 .000
120
Pearson Chi-Square
Continuity Correctiona
Likelihood Ratio
Fisher's Exact Test
Linear-by-Linear
Association
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
Exact Sig.
(2-sided)
Exact Sig.
(1-sided)
Computed only for a 2x2 tablea. 
0 cells (.0%) have expected count less than 5. The minimum expected count is 26.
50.
b. 
HDL | LDL X  Diagnosis 
TABLE 10 
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Crosstab
16 32 48
43.2% 86.5% 64.9%
21 5 26
56.8% 13.5% 35.1%
37 37 74
100.0% 100.0% 100.0%
Count
% within Diagnosis
Count
% within Diagnosis
Count
% within Diagnosis
< 4.4
> 4.5
TC | HDL
MALE
Total
Non Diabetics
with stroke Control
Diagnosis
Total
Chi-Square Tests
15.179b 1 .000
13.341 1 .000
16.024 1 .000
.000 .000
14.974 1 .000
74
Pearson Chi-Square
Continuity Correctiona
Likelihood Ratio
Fisher's Exact Test
Linear-by-Linear
Association
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
Exact Sig.
(2-sided)
Exact Sig.
(1-sided)
Computed only for a 2x2 tablea. 
0 cells (.0%) have expected count less than 5. The minimum expected count is 13.
00.
b. 
TC | HDL MALE X  Diagnosis 
TABLE 11 
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Crosstab
5 15 20
21.7% 65.2% 43.5%
18 8 26
78.3% 34.8% 56.5%
23 23 46
100.0% 100.0% 100.0%
Count
% within Diagnosis
Count
% within Diagnosis
Count
% within Diagnosis
< 3.9
>_ 4.0
TC | HDL
FEMALE
Total
Non Diabetics
with stroke Control
Diagnosis
Total
Chi-Square Tests
8.846b 1 .003
7.165 1 .007
9.180 1 .002
.007 .003
8.654 1 .003
46
Pearson Chi-Square
Continuity Correctiona
Likelihood Ratio
Fisher's Exact Test
Linear-by-Linear
Association
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
Exact Sig.
(2-sided)
Exact Sig.
(1-sided)
Computed only for a 2x2 tablea. 
0 cells (.0%) have expected count less than 5. The minimum expected count is 10.
00.
b. 
TC | HDL FEMALE X  Diagnosis  
TABLE 12 
 
 
 
 
 
 
 
80 
 
Crosstab
34 52 86
56.7% 86.7% 71.7%
26 8 34
43.3% 13.3% 28.3%
60 60 120
100.0% 100.0% 100.0%
Count
% within Diagnosis
Count
% within Diagnosis
Count
% within Diagnosis
< 30
>_ 30
VLDL
Total
Non Diabetics
with stroke Control
Diagnosis
Total
Chi-Square Tests
13.297b 1 .000
11.860 1 .001
13.829 1 .000
.000 .000
13.186 1 .000
120
Pearson Chi-Square
Continuity Correctiona
Likelihood Ratio
Fisher's Exact Test
Linear-by-Linear
Association
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
Exact Sig.
(2-sided)
Exact Sig.
(1-sided)
Computed only for a 2x2 tablea. 
0 cells (.0%) have expected count less than 5. The minimum expected count is 17.
00.
b. 
VLDL X  Diagnosis 
TABLE 13 
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DISCUSSION ABOUT THE TABLES 
 
TABLE : 1  
The data on group statistics shows the association between  
non-diabetics with stroke and their control with age. The mean age for 
non-diabetics with stroke is 58.62 and the standard deviation is 12.209.  
In controls the mean age is 58.20 and the standard deviation is 
11.725. maximum number of patients occur in the age group of 41-60 
years in both controls and patients is 48.3%  
Significance is 1.0 which in not statistically significant. 
TABLE : 2 
The data on group statistics shows the association between  
non-diabetics with stroke and their control with BMI. The mean BMI of 
non-diabetics with stroke is 24.911 and the standard deviation is 2.92865.  
In controls the mean BMI is 24.91 and the standard deviation is 
1.83. Maximum patients in the non- diabetic stroke group fall in 
overweight category and is 50%. In control group the maximum number 
of patients fall in normal category and is 66.7% significance is 0.106 
which is not significant statistically. 
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TABLE : 3 
The data shows association between non-diabetics with stroke and 
their control with sex. In both patients and controls male constituted 
61.7% and female constituted 38.3%. the significance was 1.0 is not 
statistically significant. 
TABLE : 4 
The data shows association between non-diabetics with stroke and 
their control with smoking. In non-diabetes with stroke smokers 
constituted 23.3% and control group had no smokers. The significance 
was 0.000 (P< 0.001) and is highly significant. 
TABLE : 5 
The data shows association of non-diabetics with stroke and their 
control with hypertension. In patients 23.3% were associated with 
hypertension and in control group had no hypertension. The significance 
was 0.000 ( P<0.0001) and is highly significant. 
TABLE : 6 
The data shows associations of non-diabetics with stroke and their 
controls with total cholesterol 43.3% of stroke patients had normal total 
cholesterol value and 56.7% had high total cholesterol values. In control 
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group 90% had normal total cholesterol values and 10% had high T. 
cholesterol values. The significance calculated was 0.000 (P<0.001) 
which is highly significant. 
TABLE : 7 
The data shows association of non-diabetics with stroke and their 
controls with triglycerides 58.3% of non – diabetics with stroke had 
normal triglycerides and 41.7% of non – diabetics had elevated 
triglycerides. In control group 86.7% had normal triglycerides and 13.3% 
had elevated triglycerides, the significance calculated was 0.002 (P < 
0.05) which is significant. 
TABLE : 8 
The data shows association of non- diabetics with stroke and the 
controls to high density lipoproteins. Majority of the patients with stroke. 
53.3 % had low HDL Values in contrast to controls. Where 63.3% had 
high HDL values. The significance calculated was 0.067 which is not 
significant. 
TABLE : 9 
The data shows association of non-diabetics with stroke and the 
controls to low density lipoproteins. Only 35% of the patients had normal  
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LDL cholesterol values, 65% of the patients had high LDL cholesterol 
values. In control group 91.7% had normal LDL cholesterol values. The 
remarking 8.3% had high LDL values. The significant calculated was 
0.000 (P>0.001) is highly significant. 
TABLE : 10 
The data shows association of non-diabetics with stroke and controls 
with HDL / LDL ratio. In non-diabetics with stroke majority 71.7% had 
HDL/LDL ratio <0.39 only 28.3% of stroke patients had normal HDL / 
LDL ratio more than 0.4. In control group 83.3% had HDL / LDL ratio 
>0.4 which is normal. Remaining controls 16.7% had low HDL / LDL 
values. The significance calculated was 0.000 (P<0.001) which is highly 
significant. 
TABLE : 11 
The data shows association of non – diabetics with stroke and controls 
with TC / HDL ratio in male. In 56.8% of non-diabetics with stroke had 
TC / HDL ratio > 4.5. The TC / HDL in non-diabetics with stroke < 4.4 
were 43.2%. In control group 86.5% had TC / HDL ratio <4.4 which is 
normal. In control group 13.5% had TC / HDL ratio > 4.5. On calculation 
significance was 0.000 is highly significant (P<0.001). 
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TABLE : 12 
The data shows association of non – diabetics with stroke and control 
with TC / HDL ratio in female. In 78.3% had TC / HDL ratio > 4.0 only 
21.74% had TC / HDL < 3.9 which is normal. In control group 65.2% had 
TC / HDL ratio < 3.9. 34.8% of the control had TC / HDL ratio > 4.0. 
The statistically significance calculated was 0.003 which is significant P 
value < 0.05. 
TABLE : 13 
The data shows association of non –diabetics with stroke and 
control with VLDL cholesterol  56.7% of non – diabetics VLDL < 30. In 
43.3% of patient showed VLDL > 30. In control group 86.7% had VLDL 
< 30 and 13.3 % of control had VLDL > 30. Significance calculated was 
0.000 P (<0.001) which is highly significant.  
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0
10
20
30
40
50
Non diabetics with stroke Control
8.3 8.3
48.3 48.3
43.3
43.3
%
Comparison between age group  and diagnosis
< 40 years 41 - 60 years > 60 years
AGE X DIAGNOSIS 
 
 
In both control groups and people with non-diabetic stroke<40 
years is 8.3%. In 41-60 years its 48.3% and > 60 years is 43.3%. 
Maximum number of patients in 41-60 years group is 48.3%. 
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0
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Non diabetics with stroke Control
61.7 61.7
38.3 38.3
%
Comparison between sex and diagnosis
Male Female
SEX X DIAGNOSIS 
Gender Non diabetics with stroke Control 
Male 61.7 61.7 
Female 38.3 38.3 
 
 
 
 
 
   
Graph 2 shows sex-wise distribution. In both groups, 61.7% of the 
patients were males and 38.3 % were females. Male to female ratio is 
1.61:1. 
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BMI X DIAGNOSIS 
BMI Non diabetics with stroke Control 
Under weight 1.7 0 
Normal 46.7 66.7 
Over weight 50 33.3 
Obese 1.7 0 
 
 
Graph 3 shows comparison between BMI in non-diabetics with 
stroke and control. In non-diabetics, 1.7% was under-nourished, 46.7% 
was normal, 50% overweight, 1.7% obese. Maximum number of patients- 
50% was over-weight. In control 66.7% was normal and 33.3% was over-
weight. 
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100
Non diabetics with stroke Control
23.3
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76.7
100
%
Comparison between smoking and diagnosis
Yes No
SMOKING X DIAGNOSIS 
 
 
 
 
 
 In non-diabetics with stroke, 23.3 % were smokers and 76.7% were 
non-smokers. In control group, 100% were smokers 
 
 
SMOKING Non diabetics with stroke Control 
Yes 23.3 0 
No 76.7 100 
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100
Non diabetics with stroke Control
23.3
0
76.7
100
%
Comparison between hypertension and diagnosis
Yes No
HYPERTENSION X DIAGNOSIS 
Hypertension Non diabetics with stroke Control 
Yes 23.3 0 
No 76.7 100 
 
 
 
 Graph 5 shows, 23.3% of non-diabetics with stroke had 
hypertension, 76.7% of the same group were normo-tensives. All controls 
100% were normo-tensives. 
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0
20
40
60
80
100
Non diabetics with stroke Control
43.3
90
16.7
5
40
5
%
Comparison between T.cholesterol and diagnosis
< 200 200 - 240 > 240
TOTAL CHOLESTEROL X DIAGNOSIS 
Total Cholesterol Non diabetics with stroke Control 
< 200 43.3 90 
200 – 240 16.7 5 
> 240 40 5 
 
 
 43.3% of non-diabetics with stroke has total cholesterol less than 
200. 16.7% of the same group had cholesterol 200-240. 40% of the same 
group has cholesterol more than 240%. Maximum patients 43.3 % has 
normal levels of total cholesterol. In controls, 90% have normal 
cholesterol values less than 200. 5% has cholesterol 200-240. 5% has 
cholesterol more than 240. 
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0
20
40
60
80
100
Non diabetics with stroke Control
58.3
86.7
26.7
6.7
15
6.7
%
Comparison between TGL and diagnosis
< 150 150 - 199 > 200
TRIGLYCERIDES X DIAGNOSIS 
Triglycerides Non Diabetics with Stroke Control 
< 150 58.3 86.7 
150 – 199 26.7 6.7 
> 200 15 6.7 
 
 
 In non-diabetics with stroke, less than 150 triglyceride value was 
58.3%; 150-199 was 26.7%. > 200 was 15%. Maximum patients, 58.3% 
has normal tri-glycerides.In controls, 86% has triglyceride<150, 6% has 
150-199%, in 6% more than 200. Maximum controls 86% has normal 
triglyceride values. 
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Comparison between HDL and diagnosis
< 40 > 40
HDL X DIAGNOSIS 
HDL Non diabetics with stroke Control 
< 40 53.3 36.7 
> 40 46.7 63.3 
 
 
 In non-diabetics with stroke, 53.3% had Hdl cholesterol < 40. And 
46.7 % had Hdl cholesterol >40%. Maximum number of patients 53.3% 
had low HDL cholesterol. In control group, 36.7% had HDL < 40. 63.3% 
had HDL>40%. Maximum number of controls 63.3% had normal HDL 
values. 
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35
91.7
8.3
0
16.7
5
40
3.3
%
Comparison between LDL and diagnosis
< 100 100 - 130 131 - 160 > 160
LDL X DIAGNOSIS 
LDL Non diabetics with stroke Control 
< 100 35 91.7 
100 – 130 8.3 0 
131 – 160 16.7 5 
> 160 40 3.3 
 
 
 In non-diabetics with stroke, 35% had LDL<100, 8.3% had 
LDL 100-130, 15.7% had LDL 131-160, 40% had LDL > 160. Maximum 
number of patients 40% had LDL >160. In controls, 91.7 % has normal 
LDL values< 100. 5% had LDL 131-160. 8.3% had LDL >160. 
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Non diabetics with stroke Control
71.7
16.7
28.3
83.3
%
Comparison between HDL / LDL and diagnosis
< 0.39 > 0.4
HDL / LDL X DIAGNOSIS 
HDL/LDL Non diabetics with stroke Control 
< 0.39 71.7 16.7 
> 0.4 28.3 83.3 
 
 
 
 In non-diabetics with stroke, 71.7 % had HDL/LDL  ratio<0.39. 
only 28.3% of the same group had HDL/LDL ratio>0.4%. In control 
group, 83.3% had HDl/LDL ratio >0.4. and 16.7% had HDL/LDL 
ratio>0.4. 
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Comparison between TC / HDL - male  and diagnosis
< 4.4 > 4.5
TC / HDL X DIAGNOSIS – MALE 
 
 
 
 
 
 In non-diabetic stroke males, 56.8% has TC/HDL >4.5 and 43.2% 
has <4.4. maximum number of patients had  TC/HDL ratio. In control 
group, 86.5% has TC/HDL  ratio in males <4.4 and 13.5% had > 4.5 
 
 
TC/HDL Non diabetics with stroke Control 
< 4.4 43.2 86.5 
> 4.5 56.8 13.5 
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Comparison between TC / HDL  - female  and diagnosis
< 3.9 > 4.0
TC / HDL  X DIAGNOSIS - FEMALE 
 
 
 
  
  
In non-daibetic stroke with females, maximum number had 78.3% 
has TC/HDL  ratio >4. And 21.7% had ratio less than 3.9%. in control 
group, maximum number of controls, 65.2% has TC/HDL < 3.9. 35.8% 
has TC/HDL more than 4. 
 
TC/HDL Non diabetics with stroke Control 
< 3.9 21.7 65.2 
> 4.0 78.3 34.8 
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Comparison between VLDL  and diagnosis
< 30 > 30
VLDL X DIAGNOSIS 
 
 
 
 
  
 In non-diabetics with stroke, 56.7% had VLDL< 30. 43.3% had 
VLDL >30%. Maximum number of patients has VLDL normal values. 
86.7% of controls had normal VLDL <30%. 13.3% of controls have high 
VLDL values >30. 
 
VLDL Non diabetics with stroke Control 
< 30 56.7 86.7 
> 30 43.3 13.3 
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DISCUSSION 
Association of total Cholesterol to Non diabetics with stroke 
In our study conducted on 60 patients showed total cholesterol was 
elevated in non- diabetics with stroke compared to the control group was 
highly significant P<0.001. 
A study on lipid profile in non-diabetics with stroke done by 
Sreedharan-2 et al in 2010 showed a definite increase in serum total 
cholesterol in non- diabetic stroke patients when compared to control 
groups. In his study he showed both ischemic and hemorrhagic stroke are 
associated with increased cholesterol levels. 
Benfante et al-17 (stroke 1994) showed elevated serum cholesterol 
is a risk factor for both coronary heart disease and thromboembolic stroke 
in Hawaiian Japanese Men. 
Di Mascio et al showed a positive association between risk of 
stroke and serum cholesterol. 
Iso-31 et al emphasised an inverse association between serum 
cholesterol level and hemorrhagic stroke but in his study there was a 
positive association with non – hemorrhagic stroke. 
100 
 
Tanizaki et al had showed total cholesterol was an  addition risk 
factor for cardio embolic stroke in females. 
Linden strorn et al in 1994 showed low total cholesterol levels 
decrease stroke in coronary artery disease patient. 
Alok Mohankar et al 1993 observed increase total cholesterol lead 
to increased incidence of atherosclerosis of large vessels. Atherosclerosis 
is a  definite risk factor for stroke. 
Triglycerides association with non – diabetic stroke 
 The serum triglycerides were high in our patients compared to the 
control group of our study showing statistical significance ( P<0.05) 
 Sreedharan-2 et al in his study showed 80% of non-diabetic stroke 
patients with S.triglyceride >200mg/dl had ischemic stroke and the 
remaining 20% had hemorrhagic stroke. 
 Tilvis R.S.-4 et al in his study had showed serum triglyceride is 
higher in ischemic stroke. Farid et al also had similar results in his study 
in 1972. 
 Albucher J.K-12 et al 2000 has showed serum triglycerides in 
normal range in his study on stroke. 
101 
 
 Hachinski-20 et al showed a positive association of triglycerides in 
patients of atherothrombotic stroke and transient ischemic attacks.  
Association of serum HDL Cholesterol 
 The levels of serum HDL cholesterol is not significant in this study 
conducted on 60 non-diabetic stroke patients. 
 Simons et al study revealed HDL cholesterol had protective effect 
on ischemic stroke. 
The northern Manhattan study on stroke in 2001, concluded higher 
values of HDL cholesterol was associated with reduced risk of stroke. 
Alok Mohankar-3, Ravindrakumar in 1993 showed increased LDL 
levels and low HDL levels were associated with atherosclerosis. 
Wanna Mithee S.G et al had shown high HDL levels were 
associated with decreased non fatal stroke risk.  
A study by Rubens et al in 2001 showed Gemfibrosil which raises 
HDL – cholesterol level decrease ischemic stroke by 31% in men. 
Albucher-12 et al study clearly indicated HDL – Cholesterol as the 
only lipid associated with stroke risk. He emphasised the need for 
management of low HDL cholesterol in young patients regardless of 
atherosclerosis. 
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Association of serum LDL Cholesterol 
 The levels of serum LDL cholesterol was highly significant in our 
study conducted on 60 non – diabetics with stroke ( P < 0.001) 
 Sreedharan -2et al showed raised levels of serum LDL cholesterol 
had significant risk of ischemic stroke in non-diabetics. 
 Bolet et al and Hachinski-8 et al have showed positive correlation 
between LDL cholesterol levels and risk of stroke.  
Anseil B.J et al in 2000 showed patients with established 
atherosclerosis showed are treated with statins to lower LDL cholesterol 
levels < 100 mg to decrease the incidence of stroke. 
Kurth T-6 et al 2007 showed remarkable increase in serum LDL 
levels in ischemic stroke patients. 
VLDL :- 
 VLDL levels were significantly elevated in our study conducted on 
60 non-diabetics with stroke and control group. 
Bidyadhar-7 et al 1984 showed that VLDL was raised in their study 
on stroke. 
Sreedharan -2et al in his study showed high VLDL was not 
associated with risk of stroke in non-diabetic patients.   
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CONCLUSION 
Our study was conducted on 60 non-diabetic stroke patients and 60 
controls. Exclusion was done because diabetes is associated with 
hyperlipidemia and atherosclerosis. 
This study showed significant association of total cholesterol, 
triglycerides, LDL cholesterol in non-diabetics with stroke. High levels of 
total cholesterol, triglycerides, LDL cholesterol are associated with higher 
risk of stroke. 
Lowered HDL cholesterol levels were not significantly associated 
with stroke. The ratio of HDL/LDL Cholesterol, TG/HDL cholesterol 
was calculated. 
Dyslipidemia is a tip in iceberg. Dyslipidemia if properly treated being 
a modifiable risk factor for stroke it decreasing the incidence of stroke 
due to dyslipidemia. This leads to decreased morbidity and mortality 
leading to a healthier society. 
 
LIMITATIONS 
A prospective study of non-diabetic stroke patients with follow up 
would have been of greater value to draw more definitive conclusion. 
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ABBREVIATIONS 
1. CVA- Cerebro vascular accident 
2. TIA- Transient ischemic attack 
3. WHO- World health organisation 
4. RIND- Reversible ischemic neurological deficit 
5. LDL- Low density lipo-protein 
6. HDL- High density lipo-protein 
7. VLDL- Very low density lipo-protein 
8. IDL- Intermediate density lipo-protein 
9. LCAT- Lecithin cholesterol acyl transferase 
10. T.Cholesterol- Total cholesterol 
11. HMG CoA- 3-Hydroxy 3-Methyl glutarate co-enzyme A 
12. ANA- Anti-Nuclear antibodies 
13. MCA- Middle cerebral artery 
14. LPL- Lipo protein lipase 
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MASTER CHART 
S.No. Name Age Sex Diagnosis Ht Wt BMI Smoking 
Hyper 
tension T.cho T.gly HDL LDL VLDL 
HDL | 
LDL 
TC | 
HDC 
1 RAMACHANDRAN 60 M 
Non Diabetics 
with stroke 160 60 23.43 - - 271 146 60 181.8 29.2 0.33 4.51 
2 RAMAN 64 M 
Non Diabetics 
with stroke 158 65 26.03 + + 247 132 42 178.6 26.4 0.23 5.88 
3 SYED JALAL 73 M 
Non Diabetics 
with stroke 170 84 29.06 - - 126 134 28 71.2 26.8 0.39 4.5 
4 VIJAYAGOPAL 56 M 
Non Diabetics 
with stroke 164 74 27.5 + - 212 119 48 140.2 23.8 0.34 4.41 
5 GOVINDASAMY 51 M 
Non Diabetics 
with stroke 172 68 22.98 - - 267 156 36 199.8 31.2 0.18 7.41 
6 KUPPUSAMY 50 M 
Non Diabetics 
with stroke 160 64 25 - - 184 133 46 111.4 26.6 0.41 4 
7 HAKKIM 41 M 
Non Diabetics 
with stroke 168 76 26.92 - - 280 158 34 214.4 31.6 0.15 8.23 
8 BABU 36 M 
Non Diabetics 
with stroke 155 64 23.5 + + 146 112 54 69.6 22.4 0.77 2.7 
9 RAJAGURU 32 M 
Non Diabetics 
with stroke 163 73 27.47 - - 257 163 32 192.4 32.6 0.16 8 
10 VENUGOPAL 80 M 
Non Diabetics 
with stroke 161 62 23.91 + + 254 136 53 173.8 27.2 0.29 4.7 
11 BABU 35 M 
Non Diabetics 
with stroke 154 66 27.82 + - 257 171 62 160.8 34.2 0.38 4.14 
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12 SANTHANAM 56 M 
Non Diabetics 
with stroke 174 66 21.8 - + 124 112 31 70.6 22.4 0.43 4 
13 SALEEM 36 M 
Non Diabetics 
with stroke 168 74 26.21 + + 253 227 56 151.6 45.4 0.36 4.51 
14 
SENTHIL 
MURUGAN 36 M 
Non Diabetics 
with stroke 156 84 34.51 - + 100 110 28 50 22 0.56 3.57 
15 SUBRAMANIYAN 58 M 
Non Diabetics 
with stroke 162 56 21.33 - - 232 164 51 148.2 32.8 0.34 4.54 
16 RAYAPPAN 60 M 
Non Diabetics 
with stroke 158 68 27.23 - - 248 122 33 190.6 24.8 0.17 7.51 
17 KAMARAJ 54 M 
Non Diabetics 
with stroke 154 60 25.29 + - 168 136 58 82.8 27.2 0.69 2.89 
18 DURAI 45 M 
Non Diabetics 
with stroke 168 64 22.67 - - 138 107 36 80.6 21.4 0.44 3.83 
19 KIRUBAKARAN 75 M 
Non Diabetics 
with stroke 159 67 26.5 - - 261 168 63 164.4 33.6 0.38 4.14 
20 MATHIVANAN 54 M 
Non Diabetics 
with stroke 163 73 27.47 + + 120 133 60 33.4 26.6 1.81 2 
21 KENGAN 65 M 
Non Diabetics 
with stroke 171 68 23.25 + - 251 181 43 171.8 36.2 0.3 5.83 
22 NARAYANAN 58 M 
Non Diabetics 
with stroke 176 62 20.01 - - 243 214 37 163.2 42.8 0.22 6.56 
23 RAJENDRAN 65 M 
Non Diabetics 
with stroke 152 58 25.1 + + 108 107 47 39.6 21.4 1.175 2.29 
24 MURUGAN 46 M 
Non Diabetics 
with stroke 163 63 23.71 + + 244 148 34 180.4 29.6 0.18 7.17 
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25 MUNUSAMY 67 M 
Non Diabetics 
with stroke 168 59 20.9 - - 103 124 51 27.2 24.8 1.875 2.019 
26 SEKAR 50 M 
Non Diabetics 
with stroke 148 55 25.11 + - 242 174 29 178.2 34.8 0.162 8.34 
27 SHANMUGAM 62 M 
Non Diabetics 
with stroke 157 52 21.09 - + 224 136 53 143.8 27.2 0.36 4.22 
28 RANGANATHAN 78 M 
Non Diabetics 
with stroke 154 50 21.08 - - 148 96 50 78.8 19.2 0.63 2.96 
29 NITHYA NANDHAN 41 M 
Non Diabetics 
with stroke 159 58 22.9 + - 107 129 33 48.2 25.8 0.68 3.2 
30 GOPALAN 95 M 
Non Diabetics 
with stroke 158 62 24.83 - - 251 146 47 174.8 29.2 0.268 5.3 
31 MUNUSAMY 62 M 
Non Diabetics 
with stroke 163 61 22.96 - + 304 204 42 221.2 40.8 0.19 7.2 
32 SIVARAMAN 48 M 
Non Diabetics 
with stroke 168 66 23.38 - - 168 132 27 114.6 26.4 0.23 6.2 
33 RAJU 57 M 
Non Diabetics 
with stroke 162 72 27.43 - - 272 230 43 183 46 0.23 6.32 
34 CHINNAPPAN 64 M 
Non Diabetics 
with stroke 155 58 24.14 - - 156 121 34 100.8 24.2 0.3 5.03 
35 NAGARAJAN 59 M 
Non Diabetics 
with stroke 153 57 24.35 - + 220 153 46 143.4 30.6 0.32 4.7 
36 RAVI 66 M 
Non Diabetics 
with stroke 156 63 25.88 - - 232 204 37 154.2 40.8 0.23 6.27 
37 MUNUSAMY 83 M 
Non Diabetics 
with stroke 164 63 23.42 + - 135 116 51 60.8 23.2 0.83 2.6 
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38 PRABAVATHY 50 F 
Non Diabetics 
with stroke 157 54 21.9 - - 248 107 29 197.6 21.4 0.14 8.5 
39 JAIRUBA 63 F 
Non Diabetics 
with stroke 158 60 24.03 - - 246 158 50 164.4 31.6 0.3 4.92 
40 PONNUMANI  58 F 
Non Diabetics 
with stroke 155 58 24.18 - - 101 96 32 49.8 19.2 0.64 3.15 
41 VIMALA 68 F 
Non Diabetics 
with stroke 156 71 29.17 - - 218 163 48 138 32.6 0.34 4.54 
42 HEMALATHA 58 F 
Non Diabetics 
with stroke 155 58 24.14 - + 170 108 37 112 21.6 0.33 4.59 
43 SHOBA 46 F 
Non Diabetics 
with stroke 157 63 25.55 - - 247 174 45 167.2 34.8 0.26 5.48 
44 VIDHYA 59 F 
Non Diabetics 
with stroke 148 55 25.11 - - 144 102 34 89.6 20.4 0.37 4.23 
45 ANDAL 57 F 
Non Diabetics 
with stroke 162 72 27.43 - + 216 182 39 140.6 36.4 0.27 5.53 
46 ROJA 67 F 
Non Diabetics 
with stroke 163 70 26.34 - - 103 112 43 37.6 22.4 1.13 2.39 
47 PREMA 58 F 
Non Diabetics 
with stroke 160 72 28.12 - - 159 142 36 94.6 28.4 0.37 4.41 
48 PANCHALI 70 F 
Non Diabetics 
with stroke 161 62 23.91 - - 212 155 41 140 31 0.29 5.1 
49 JAYANTHI 67 F 
Non Diabetics 
with stroke 154 66 27.82 - - 283 306 28 193.8 61.2 0.14 10.1 
50 RAVANAMME 64 F 
Non Diabetics 
with stroke 158 68 27.23 - - 127 102 47 59.6 20.4 0.78 2.7 
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51 RANGANAYAKI 64 F 
Non Diabetics 
with stroke 151 61 26.75 - - 147 104 27 99.2 20.8 0.27 5.44 
52 SUMATHY 62 F 
Non Diabetics 
with stroke 147 59 27.3 - - 256 204 34 181.2 40.8 0.18 7.52 
53 RUKMANI 54 F 
Non Diabetics 
with stroke 153 68 29.05 - - 143 108 26 95.4 21.6 0.27 5.5 
54 MAHESWARI 60 F 
Non Diabetics 
with stroke 157 46 18.66 - - 250 160 28 190 32 0.14 8.92 
55 BANU 52 F 
Non Diabetics 
with stroke 150 40 17.76 - - 234 168 33 168 33.6 0.19 7.09 
56 LEELAVATHY 75 F 
Non Diabetics 
with stroke 149 58 26.12 - - 107 96 37 51 19.2 0.72 2.89 
57 RADHA 68 F 
Non Diabetics 
with stroke 154 62 26.14 - - 168 132 31 111 264 0.27 5.41 
58 RAGANAMMA 62 F 
Non Diabetics 
with stroke 151 44 19.3 - - 230 206 36 153 41.2 0.23 6.38 
59 KALPANA 61 F 
Non Diabetics 
with stroke 148 61 27.85 - - 104 98 35 50 19.6 0.7 2.97 
60 BAGAVATHI 56 F 
Non Diabetics 
with stroke 156 60 24.65 - - 258 208 28 189 41.6 0.14 9.21 
61 PALANI 57 M CONTROL 154 58 24.46 - - 166 134 48 91.2 26.8 0.52 3.45 
62 AMUDHAN 65 M CONTROL 150 60 26.67 - - 132 120 34 74 24 0.45 3.88 
63 ANANDHAN 44 M CONTROL 156 64 26.3 - - 162 132 42 93.6 26.4 0.44 3.85 
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64 VELU 74 M CONTROL 160 68 26.5 - - 148 121 44 79.8 24.2 0.55 3.36 
65 MARIMUTHU 80 M CONTROL 148 54 24.65 - - 151 123 43 83.4 24.6 0.51 3.51 
66 RAJAGURU 60 M CONTROL 157 66 26.78 - - 131 156 36 63.8 31.2 0.56 3.04 
67 RAMESH 52 M CONTROL 162 70 26.67 - - 243 162 53 157.6 32.4 0.33 4.58 
68 PRAKASH 37 M CONTROL 158 60 24.03 - - 128 124 44 59.2 24.8 0.74 2.9 
69 VELAN 50 M CONTROL 150 65 28.89 - - 134 121 43 66.8 24.2 0.643 3.11 
70 MURUGAN 34 M CONTROL 162 54 20.58 - - 124 126 50 48.8 25.2 1.02 2.48 
71 MANOHAR 37 M CONTROL 156 62 25.48 - - 156 131 45 84.8 26.2 0.53 3.46 
72 MADHAVAN 59 M CONTROL 154 60 25.3 - - 138 125 38 75 25 0.5 3.63 
73 CHINNAPPAN 55 M CONTROL 157 64 25.96 - - 140 123 51 64.4 24.6 0.791 2.745 
74 SELVAKUMAR 58 M CONTROL 160 70 27.34 - - 246 204 47 158.2 40.8 0.297 5.23 
75 SURYA 34 M CONTROL 162 64 24.39 - - 142 127 53 63.6 25.4 0.83 2.67 
76 VIMALAN 46 M CONTROL 163 58 21.83 - - 148 128 43 79.4 25.6 0.541 3.44 
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77 VIJAYAKUMAR 37 M CONTROL 158 60 24.03 - - 140 130 34 80 26 0.425 4.11 
78 VAIDHIYANADHAN 76 M CONTROL 151 54 23.68 - - 156 129 49 81.2 25.8 0.603 3.18 
79 SRIDHAR 60 M CONTROL 168 60 21.26 - - 143 133 44 72.4 26.6 0.607 3.25 
80 PRABAKARAN 55 M CONTROL 160 54 21.09 - - 151 120 36 91 24 0.395 4.19 
81 PUNYAKODI 59 M CONTROL 154 64 26.99 - - 137 204 50 46.2 40.8 1.08 2.74 
82 DHARMAN 66 M CONTROL 159 63 24.92 - - 143 121 37 81.8 24.2 0.45 3.86 
83 DEIVEGAN 48 M CONTROL 160 57 22.27 - - 150 131 44 69.8 26.2 0.63 3.4 
84 MANIVANNAN 66 M CONTROL 162 70 26.67 - - 238 126 50 162.8 25.2 0.3 4.76 
85 VASAN 69 M CONTROL 161 58 22.38 - - 151 134 43 81.2 26.8 0.52 3.51 
86 VAIRAM 63 M CONTROL 158 62 24.84 - - 154 125 33 96 25 0.34 4.66 
87 SARAVANAN 50 M CONTROL 152 57 24.67 - - 140 127 41 73.6 25.4 0.55 3.41 
88 SHANMUGAN 75 M CONTROL 168 60 21.26 - - 138 130 51 61 26 0.83 2.7 
89 SRIDHAR 43 M CONTROL 161 63 24.3 - - 143 128 48 69.4 25.5 0.69 2.97 
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90 VELAN 91 M CONTROL 163 68 25.59 - - 151 133 46 78.6 26.6 0.58 3.28 
91 THANIKACHALAM 63 M CONTROL 162 66 25.15 - - 138 131 43 68.8 26.2 0.625 3.2 
92 MAGESWARAN 46 M CONTROL 156 54 22.19 - - 142 120 33 85 24 0.38 4.3 
93 DIVAKARAN 55 M CONTROL 153 58 24.78 - - 126 122 51 50.6 24.4 1.007 2.47 
94 SIVALINGAM 66 M CONTROL 158 62 24.84 - - 212 131 36 49.8 26.2 0.24 5.8 
95 THENNAPPAN 57 M CONTROL 163 67 25.22 - - 131 124 45 61.2 24.8 0.735 2.9 
96 BALU 64 M CONTROL 160 70 27.34 - - 128 123 39 64.4 24.6 0.6 3.28 
97 KIRUBAKARAN 81 M CONTROL 158 60 24.03 - - 137 126 34 77.8 25.2 0.43 4.02 
98 DHANABAKYAM 55 F CONTROL 152 51 22.07 - - 142 120 41 77 24 0.53 3.46 
99 ESAIVANI 50 F CONTROL 154 58 24.46 - - 124 204 43 40.2 40.8 1.06 2.88 
100 SARASWATHY 61 F CONTROL 160 64 25 - - 128 131 35 66.8 26.2 0.52 3.65 
101 VASUKI 67 F CONTROL 147 55 25.45 - - 138 160 46 60 32 0.76 3 
102 MARIYAMMA 55 F CONTROL 154 60 25.3 - - 142 121 35 82.8 24.2 0.42 4.05 
122 
 
103 RANI 43 F CONTROL 158 62 24.84 - - 121 133 44 50.4 26.6 0.87 2.75 
104 PARVATHI 55 F CONTROL 155 50 20.81 - - 206 158 34 140.4 31.6 0.24 6.05 
105 PECHAIAMMA 52 F CONTROL 153 55 23.5 - - 137 126 33 78.8 25.2 0.41 4.151 
106 ELIZABETH 53 F CONTROL 160 64 25 - - 150 202 58 51.6 40.4 1.12 2.586 
107 SARADHA 63 F CONTROL 157 54 21.91 - - 149 124 31 93.2 24.8 0.33 4.806 
108 NIRMALA 65 F CONTROL 159 63 24.92 - - 242 131 53 162.8 26.2 0.32 4.56 
109 NARASAMMA 70 F CONTROL 152 49 21.21 - - 146 133 39 80.4 26.6 0.48 3.74 
110 DIVYA 63 F CONTROL 151 55 24.12 - - 151 131 51 73.8 26.2 0.69 2.96 
111 SATHYA 62 F CONTROL 154 56 23.61 - - 144 121 54 65.8 24.2 0.82 2.6 
112 RADHA 63 F CONTROL 158 60 24.03 - - 151 124 32 94.2 24.8 0.33 4.71 
113 SUJATHA 51 F CONTROL 157 61 24.75 - - 153 123 51 77.4 24.6 0.65 3 
114 SUDHA 53 F CONTROL 151 53 23.24 - - 147 131 35 85.8 26.2 0.4 4.2 
115 SAVITHRI 60 F CONTROL 148 52 23.74 - - 138 120 53 61 24 0.86 2.6 
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116 MADHAVI 65 F CONTROL 150 51 22.67 - - 133 122 34 74.6 24.4 0.45 3.91 
117 DEVI 73 F CONTROL 153 54 23.07 - - 156 131 38 91.8 26.2 0.41 4.1 
118 DHANAMMA 66 F CONTROL 151 55 24.12 - - 148 133 45 76.4 26.6 0.58 3.28 
119 SRIDEVI 62 F CONTROL 152 56 24.24 - - 135 128 36 73.4 25.6 0.49 3.75 
120 SUBA 53 F CONTROL 155 53 22.06 - - 151 132 44 80.6 26.4 0.54 3.43 
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